Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Pulmonary hypertension: the hallmark of acute COVID-19 microvascular angiopathy?

Sri Harsha Dintakurti, Sanjana Kamath, Ciara Mahon, Suveer Singh, Bhavin Rawal, Simon P.G. Padley, Anand Devaraj, Laura C. Price, Sujal R. Desai, Tom Semple, Carole A. Ridge
ERJ Open Research 2023 9: 00389-2022; DOI: 10.1183/23120541.00389-2022
Sri Harsha Dintakurti
1Imperial College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sri.dintakurti17@imperial.ac.uk
Sanjana Kamath
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ciara Mahon
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suveer Singh
3Department of Adult Intensive Care, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Suveer Singh
Bhavin Rawal
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon P.G. Padley
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anand Devaraj
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura C. Price
4Pulmonary Hypertension Service, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura C. Price
Sujal R. Desai
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Semple
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tom Semple
Carole A. Ridge
2Department of Imaging, Royal Brompton Hospital, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In situ pulmonary arterial thrombosis in COVID-19 is not visible on CTPA. However, the presence of CT-measured right heart and pulmonary artery dilatation in COVID-19 is likely attributable to this process and may be a possible surrogate for its detection. https://bit.ly/3g7z5TV

To the Editor:

There have been >481 million cases of COVID-19, caused by SARS-CoV-2, worldwide since December 2019 [1]. One of the hallmark features of acute COVID-19 pneumonia is pulmonary vascular involvement, most commonly manifesting as pulmonary artery thrombosis (PAT) [2, 3]. Post mortem data from 10 patients with COVID-19 pneumonia showed their central pulmonary arteries were free of thrombosis but all patients had small, firm thrombi in the peripheral parenchyma [4]. These findings raise the possibility that the computed tomography (CT) finding of isolated subsegmental PAT may reflect “the tip of the iceberg”; that small segmental thrombi may reflect downstream in situ thrombosis in the microvasculature. In patients with severe COVID-19 pneumonitis, dual-energy computed tomography pulmonary angiography (CTPA) has been used to demonstrate reduced pulmonary perfusion in the absence of any visible central thromboembolism [5, 6], further supporting the view that microscopic PAT is prevalent [6].

The microscopic presence of extensive in situ thrombosis is thought to account for the development of pulmonary hypertension in patients with acute COVID-19 pneumonia [7]. This has been confirmed invasively in some cases, and more often using echocardiography, with evidence for raised pulmonary vascular resistance and, not infrequently, right ventricular radial dysfunction [8]. Determining the extent of thrombosis and its relationship with the development of pulmonary hypertension in patients with COVID-19 is a challenge, but it may enable earlier identification and intervention.

We hypothesise that PAT – both microscopic and macroscopic – is more common in acute COVID-19 pneumonia than in influenza pneumonia. We therefore sought 1) to establish whether isolated peripheral PAT is associated with pulmonary hypertension, and 2) to compare the incidence of CT features of pulmonary hypertension in both COVID-19 and influenza infection.

This retrospective, observational, single-centre study was approved by the National Health Service Health Research Authority (approval number 20/HRA/1434).

Single- and dual-energy CTPA of age- and gender-matched patients with influenza and COVID-19 pneumonia, referred for extra-corporeal membrane oxygenation (ECMO) and/or mechanical ventilation to the adult intensive care unit (AICU), from January 2016 to January 2021, were retrospectively evaluated. From both disease cohorts, those who had an available CTPA scan on the day of their admission to AICU were considered. Eligible influenza patients were then age- and gender-matched with the COVID-19 patients. After exclusion, 25 COVID-19 and 25 influenza patients were assessed (seven females and 18 males each). No patient had a pre-existing history of pulmonary hypertension prior to COVID-19/influenza infection.

The incidence of PAT, including central and peripheral, was recorded using CTPA. Furthermore, the incidence of peripheral pulmonary artery thrombi occurring in the absence of either central pulmonary embolism or deep vein thrombosis (DVT) was recorded (i.e. isolated peripheral pulmonary artery thrombi), as an imaging surrogate for in situ thrombosis. This qualitative CTPA analysis was assessed by two observers with 15 and 10 years’ experience of CT analysis, respectively. They reviewed CT scans in a blinded manner and further quantified PAT burden using the Qanadli scoring system [9]. DVT incidence was obtained through previous Doppler ultrasonography lower limb reports.

CT signs of pulmonary hypertension, such as cardiac dimensions, were assessed using Aquarius iNtuition Viewer (Terarecon, version 4.4.13.P3A). The incidence of PAT, severity of PAT extent, and CT cardiac dimensions, pulmonary and aortic diameter, and central pulmonary artery volume were measured and compared between the two groups. Blood D-dimer levels taken on admission were collected and assessed for correlation with CT signs of pulmonary hypertension and PAT burden in each cohort (GraphPad Prism 9).

Our final age- and gender-matched study cohort comprised 50 patients (COVID-19 pneumonia, n=25; influenza pneumonia, n=25). Both cohorts consisted of 28% females (n=7) and 72% males (n=18). Mean±sd age was 49.5±11.1 and 49.4±11.1 years in the COVID-19 and influenza cohorts, respectively. There were no statistically significant differences in age, gender or body mass index between groups (table 1).

View this table:
  • View inline
  • View popup
TABLE 1

Demographic information, clinical characteristics, pulmonary artery thrombus incidence and computed tomography (CT) parameters of pulmonary hypertension of the COVID-19 and influenza study cohorts (n=50)

There was no significant difference in thrombotic burden between the COVID-19 and influenza cohorts. While the incidence of PAT was higher in COVID-19 compared to influenza infection, this difference did not reach statistical significance (60% versus 44%, respectively; p=0.3961). Interestingly, the incidence of isolated peripheral PAT (i.e. in absence of central pulmonary embolism or DVT, as a surrogate marker for in situ PAT) was similar between COVID-19 and influenza infection (44% versus 32%, p=0.5607) (table 1).

Despite this, CT signs of pulmonary hypertension were greater in COVID-19: right-to-left ventricular diameter ratio (1.16 versus 0.898, p=0.00786) and pulmonary artery to aorta diameter ratio (1.04 versus 0.705, p=0.000265) were higher in COVID-19 compared to influenza pneumonia (table 1). This trend persisted when the data were subgrouped by gender but did not reach statistical significance for both parameters, likely due to small sample size.

Levels of blood D-dimer showed no correlation to CT signs of pulmonary hypertension in either cohort; however, they did show a significant, moderate positive correlation with PAT burden in the COVID-19 cohort only (p=0.0035).

CT signs of pulmonary hypertension are more prevalent in COVID-19 compared to influenza infection but this is not attributable to PAT observable on CT. Given post mortem evidence of small pulmonary capillary occlusion by microthrombi [10], this suggests that pulmonary arterial microthrombi too small to visualise on CT might be responsible. Furthermore, it is possible that pulmonary vessel endothelialitis, also observed post mortem, may contribute to pulmonary hypertension in COVID-19 through release of vasoconstrictive inflammatory mediators [10].

Blood D-dimer levels were shown to be correlated to visible PAT burden in COVID-19 only. They may be useful in assessing the extent of PAT in severe COVID-19 and determining the requirement for anticoagulation in these patients early.

Our study does reiterate the high absolute prevalence of PAT seen in severe COVID-19 [11, 12]; however, existing literature also reports a higher PAT incidence (both overall and peripherally) in COVID-19 compared to influenza pneumonia patients receiving ECMO [13]. In contrast, we report not only similar incidences between COVID-19 and influenza, but also much higher rates of isolated peripheral PAT overall, particularly in the influenza cohort (we report 32% compared to 5% reported by Doyle et al. [13]). These differences may be explained by our age and gender cohort-matching process, which was not employed in the compared study, as the age profile of patients with severe influenza tends to be lower than in COVID-19 infection. Additionally, in contrast to other studies [14], all our influenza patients had severe acute respiratory failure (SARF) and were intubated, akin to the respiratory status of our COVID-19 patients.

A notable strength of this study is that, to the best of our knowledge, it is the first to compare isolated peripheral PAT in severe COVID-19 SARF patients requiring ECMO or mechanical ventilation to an age- and gender-matched cohort of severe non-COVID-19 pneumonia SARF patients.

In summary, we demonstrate that the likely process of in situ PAT in COVID-19 is not visible on CTPA. However, the presence of CT-measured right heart and pulmonary artery dilatation in COVID-19 is likely attributable to this process and so they may be a possible surrogate for its detection. Going forward, functional imaging such as perfusion scintigraphy and dual-energy CT should be investigated, as they may allow earlier detection in these patients prior to pulmonary hypertension CT markers developing.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: L.C. Price has received support from Janssen Pharmaceuticals and Ferrer Pharmaceuticals to attend meetings outside the submitted work, and participated on a data safety or advisory board for Janssen outside the submitted work. The remaining authors have nothing to disclose.

  • Received August 2, 2022.
  • Accepted November 8, 2022.
  • Copyright ©The authors 2023
http://creativecommons.org/licenses/by/4.0/

This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

References

  1. ↵
    1. World Health Organisation
    . WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int Date last accessed: 20 February 2021.
  2. ↵
    1. Klok FA,
    2. Kruip MJHA,
    3. van der Meer NJM, et al.
    Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thrombosis Res 2020; 191: 145–147. doi:10.1016/j.thromres.2020.04.013
    OpenUrlCrossRefPubMed
  3. ↵
    1. Helms J,
    2. Tacquard C,
    3. Severac F, et al.
    High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46: 1089–1098. doi:10.1007/s00134-020-06062-x
    OpenUrlCrossRefPubMed
  4. ↵
    1. Fox SE,
    2. Akmatbekov A,
    3. Harbert JL, et al.
    Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 2020; 8: 681–686. doi:10.1016/S2213-2600(20)30243-5
    OpenUrl
  5. ↵
    1. Patel BV,
    2. Arachchillage DJ,
    3. Ridge CA, et al.
    Pulmonary angiopathy in severe COVID-19: physiologic, imaging, and hematologic observations. Am J Respir Crit Care Med 2020; 202: 690–699. doi:10.1164/rccm.202004-1412OC
    OpenUrlCrossRefPubMed
  6. ↵
    1. Grillet F,
    2. Busse-Coté A,
    3. Calame P, et al.
    COVID-19 pneumonia: microvascular disease revealed on pulmonary dual-energy computed tomography angiography. Quant Imaging Med Surg 2020; 10: 1852–1862. doi:10.21037/qims-20-708
    OpenUrlCrossRef
  7. ↵
    1. Price LC,
    2. Garfield B,
    3. Bleakley C, et al.
    Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome. Pulm Circ 2020; 10: 2045894020973906. doi:10.1177/2045894020973906
    OpenUrl
  8. ↵
    1. Bleakley C,
    2. Singh S,
    3. Garfield B, et al.
    Right ventricular dysfunction in critically ill COVID-19 ARDS. Int J Cardiol 2021; 327: 251–258. doi:10.1016/j.ijcard.2020.11.043
    OpenUrl
  9. ↵
    1. Qanadli SD,
    2. el Hajjam M,
    3. Vieillard-Baron A, et al.
    New CT index to quantify arterial obstruction in pulmonary embolism. AJR Am J Roentgenol 2001; 176: 1415–1420. doi:10.2214/ajr.176.6.1761415
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ackermann M,
    2. Verleden SE,
    3. Kuehnel M, et al.
    Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J M 2020; 383: 120–128. https://doi.org/10.1056/NEJMoa2015432
    OpenUrlCrossRefPubMed
  11. ↵
    1. Mirsadraee S,
    2. Gorog DA,
    3. Mahon CF, et al.
    Prevalence of thrombotic complications in ICU-treated patients with coronavirus disease 2019 detected with systematic CT scanning. Crit Care Med 2021; 49: 804–815. doi:10.1097/CCM.0000000000004890
    OpenUrl
  12. ↵
    1. Ridge CA,
    2. Desai SR,
    3. Jeyin N, et al.
    Dual-energy CT pulmonary angiography (DECTPA) quantifies vasculopathy in severe COVID-19 pneumonia. Radiol Cardiothorac Imaging 2020; 2: e200428. doi:10.1148/ryct.2020200428
    OpenUrl
  13. ↵
    1. Doyle AJ,
    2. Hunt BJ,
    3. Sanderson B, et al.
    A comparison of thrombosis and hemorrhage rates in patients with severe respiratory failure due to coronavirus disease 2019 and influenza requiring extracorporeal membrane oxygenation. Crit Care Med 2021; 49: e663–e672. doi:10.1097/CCM.0000000000004971
    OpenUrl
  14. ↵
    1. Poissy J,
    2. Goutay J,
    3. Caplan M, et al.
    Pulmonary embolism in patients with COVID-19. Circulation 2020; 142: 184–186. doi:10.1161/CIRCULATIONAHA.120.047430
    OpenUrlPubMed
PreviousNext
Back to top
Vol 9 Issue 1 Table of Contents
ERJ Open Research: 9 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary hypertension: the hallmark of acute COVID-19 microvascular angiopathy?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Pulmonary hypertension: the hallmark of acute COVID-19 microvascular angiopathy?
Sri Harsha Dintakurti, Sanjana Kamath, Ciara Mahon, Suveer Singh, Bhavin Rawal, Simon P.G. Padley, Anand Devaraj, Laura C. Price, Sujal R. Desai, Tom Semple, Carole A. Ridge
ERJ Open Research Jan 2023, 9 (1) 00389-2022; DOI: 10.1183/23120541.00389-2022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pulmonary hypertension: the hallmark of acute COVID-19 microvascular angiopathy?
Sri Harsha Dintakurti, Sanjana Kamath, Ciara Mahon, Suveer Singh, Bhavin Rawal, Simon P.G. Padley, Anand Devaraj, Laura C. Price, Sujal R. Desai, Tom Semple, Carole A. Ridge
ERJ Open Research Jan 2023, 9 (1) 00389-2022; DOI: 10.1183/23120541.00389-2022
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A 3D-engineered silicone stent
  • Obesity does not modify effect of CPAP on insulin resistance
  • Asthma prevalence and medication dispensation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society